Population Pharmacokinetic Analysis for Daclatasvir and Asunaprevir in Japanese Subjects With Chronic Hepatitis C Virus Infection

Daclatasvir is a nonstructural protein 5A replication complex inhibitor, and asunaprevir is a nonstructural protein 3 protease inhibitor for hepatitis C virus (HCV). In 2014, the combination therapy of daclatasvir and asunaprevir received the first global approval in Japan as the first nonribavirin,...

Descripción completa

Detalles Bibliográficos
Autores principales: Osawa, Mayu, Ueno, Takayo, Ishikawa, Hiroki, Imai, Yasuhiko, Garimella, Tushar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Pharmacometrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174986/
https://www.ncbi.nlm.nih.gov/pubmed/30063254
http://dx.doi.org/10.1002/jcph.1274

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174986/
https://www.ncbi.nlm.nih.gov/pubmed/30063254
http://dx.doi.org/10.1002/jcph.1274

Ejemplares similares